Rebeca Nuñez

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Newly Diagnosed

Combination Therapy

Smoking Cessation

Top Venues

Journal of neuro-oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jescelica Ortiz-Rivera, Rebeca Nuñez, Yuriy V Kucheryavykh, Lilia Y Kucheryavykh
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. Journal of neuro-oncology 161 (3) (2023)
Jescelica Ortiz-Rivera, Rebeca Nuñez, Yuriy V Kucheryavykh, Lilia Y Kucheryavykh
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. Journal of neuro-oncology (2023)
Jescelica Ortiz-Rivera, Rebeca Nuñez, Yuriy V Kucheryavykh, Lilia Y Kucheryavykh
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. Journal of neuro-oncology 161 (3) (2023)
Jescelica Ortiz-Rivera, Rebeca Nuñez, Yuriy V Kucheryavykh, Lilia Y Kucheryavykh
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. Journal of neuro-oncology 161 (3) (2023)
Jescelica Ortiz-Rivera, Rebeca Nuñez, Yuriy V Kucheryavykh, Lilia Y Kucheryavykh
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. Journal of neuro-oncology 161 (3) (2023)
Jescelica Ortiz-Rivera, Rebeca Nuñez, Yuriy V Kucheryavykh, Lilia Y Kucheryavykh
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. Journal of neuro-oncology 161 (3) (2023)